glp-1 drugs for obesity Agonists: Using Semaglutide, Tirzepatide, and Orforglipron Weight Loss and What is the pipeline for

Level 2 evidence corresponds to cohort studies or systematic reviews of cohort studies

2011 Jul;34(7):1041-3

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

doi: 10.1111/gtc.12884 14 KanberDGiltayJWieczorekDZogelCHochstenbachRCaliebeAet al

While current guidelines recommend GLP-1 RAs for managing diabetes in patients with a history of stroke, there is a clear need for more specific recommendations addressing their use in stroke prevention for patients with obesity

According to the World Obesity Atlas, over 4 billion people, or 51% of the global population, by 2035 will suffer from obesity